NCT06558097View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

March 2, 2023

Study Completion Date

March 31, 2023

Conditions
XXB750 in Healthy Participants
Interventions
DRUG

XXB750

Single SC dose of XXB750 (administered by single or multiple injections)

OTHER

Placebo

Single SC dose of matching placebo (administered by single or multiple injections)

Trial Locations (1)

90630

Novartis Investigative Site, Cypress

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY